NCT07117136

Brief Summary

This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \& Translational Science Institute.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
37mo left

Started Aug 2025

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress19%
Aug 2025May 2029

First Submitted

Initial submission to the registry

August 5, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 12, 2025

Completed
16 days until next milestone

Study Start

First participant enrolled

August 28, 2025

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 14, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 14, 2029

Last Updated

November 12, 2025

Status Verified

November 1, 2025

Enrollment Period

3.7 years

First QC Date

August 5, 2025

Last Update Submit

November 8, 2025

Conditions

B-Cell Acute Lymphoblastic Leukaemia

Outcome Measures

Primary Outcomes (1)

  • Percentage of participants with complete remission

    Complete remission as defined by patients having no lymphoblasts in the marrow or blood

    5 years or e.g., 1 year after closure of study

Secondary Outcomes (1)

  • Overall Survival

    5 years

Study Arms (2)

Patients who received Blinatumomab Therapy

Patients who did not receive Blinatumomab Therapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with B-ALL diagnosed during or after December 2022

You may qualify if:

  • \) aged 18 years or older 2) diagnosed with B-ALL on or after December 1st 2023 3) Not received blinatumomab in an interventional clinical trial setting 4) Willing and able to give informed consent (or retrospective data for deceased patients

You may not qualify if:

  • N/A

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

RECRUITING

MeSH Terms

Conditions

Burkitt Lymphoma

Condition Hierarchy (Ancestors)

Epstein-Barr Virus InfectionsHerpesviridae InfectionsDNA Virus InfectionsVirus DiseasesInfectionsTumor Virus InfectionsLymphoma, B-CellLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Central Study Contacts

Blong Vang

CONTACT

4148056330bvang@mcw.edu

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

August 5, 2025

First Posted

August 12, 2025

Study Start

August 28, 2025

Primary Completion (Estimated)

May 14, 2029

Study Completion (Estimated)

May 14, 2029

Last Updated

November 12, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations

US(1)